1. Home
  2. AIHS vs BCAB Comparison

AIHS vs BCAB Comparison

Compare AIHS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIHS

Senmiao Technology Limited

HOLD

Current Price

$1.38

Market Cap

5.7M

Sector

Finance

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$3.62

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIHS
BCAB
Founded
2014
2007
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
6.4M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
AIHS
BCAB
Price
$1.38
$3.62
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
30.7K
37.1K
Earning Date
02-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
14.63
29.86
EPS
N/A
N/A
Revenue
$3,389,072.00
$300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.12
52 Week High
$8.26
$6.52

Technical Indicators

Market Signals
Indicator
AIHS
BCAB
Relative Strength Index (RSI) 58.14 53.78
Support Level $1.09 $3.19
Resistance Level $1.62 $5.18
Average True Range (ATR) 0.15 0.35
MACD 0.01 0.03
Stochastic Oscillator 62.04 69.10

Price Performance

Historical Comparison
AIHS
BCAB

About AIHS Senmiao Technology Limited

Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: